LivingGLP1
Study S000506

Effect of Exenatide Once Weekly on Cardiovascular Risk Markers in Patients With Type-2 Diabetes

ClinicalTrials.gov record

Registration

Registration
NCT02380521
Study type
INTERVENTIONAL
Phase
PHASE4
Masking
NONE
Status
COMPLETED
Enrollment
60
Start
2015-01
Primary completion
2016-07
Lead sponsor
University of Palermo
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:Exenatide once weekly (BYDUREON™)
Results posted
FALSE

Registered primary outcomes

  • Subclinical atherosclerosis (as measured by cIMT) in patients with T2DM treated with exenatide once weekly [Change from baseline to 8 months of the treatment]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0016299Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
Buse JB, Lancet (London, England)
2013Randomized trialPMID 23141817DOIregistry reference BACKGROUND:23141817
R0027761Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Russell-Jones D, Diabetes care
2012Randomized trialPMID 22210563DOIregistry reference BACKGROUND:22210563
R0027649DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T, The Journal of clinical endocrinology and metabolism
2011Randomized trialPMID 21307137DOIregistry reference BACKGROUND:21307137
R0020417Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Bergenstal RM, Lancet (London, England)
2010Randomized trialPMID 20580422DOIregistry reference BACKGROUND:20580422
R0027273Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Diamant M, Lancet (London, England)
2010Randomized trialPMID 20609969DOIregistry reference BACKGROUND:20609969
R0025313Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Drucker DJ, Lancet (London, England)
2008Randomized trialPMID 18782641DOIregistry reference BACKGROUND:18782641